Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.

Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, Zuberbier T, Maurer M.

Allergy. 2012 Jul;67(7):943-50. doi: 10.1111/j.1398-9995.2012.02843.x. Epub 2012 May 15.

PMID:
22583335
2.

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.

Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP.

Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29.

3.

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ.

Arthritis Rheum. 2008 Aug;58(8):2443-52. doi: 10.1002/art.23687.

4.

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopoulos JH, Weinstein SP, Mellis SJ, Kastner DL.

Arthritis Rheum. 2008 Aug;58(8):2432-42. doi: 10.1002/art.23620.

5.

Anakinra: an effective treatment in the Schnitzler syndrome.

Vandenhende MA, Bentaberry F, Morlat P, Bonnet F.

Joint Bone Spine. 2011 Dec;78(6):636-7. doi: 10.1016/j.jbspin.2011.03.021. Epub 2011 May 6.

PMID:
21550281
6.

Schnitzler syndrome: response to anakinra in two cases and a review of the literature.

Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W.

Int J Dermatol. 2009 Nov;48(11):1190-4. doi: 10.1111/j.1365-4632.2009.04151.x. Review.

PMID:
20064173
7.

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.

Krause K, Tsianakas A, Wagner N, Fischer J, Weller K, Metz M, Church MK, Maurer M.

J Allergy Clin Immunol. 2017 Apr;139(4):1311-1320. doi: 10.1016/j.jaci.2016.07.041. Epub 2016 Sep 19.

PMID:
27658762
8.

[Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].

Lipsker D, Lenormand C.

Ann Dermatol Venereol. 2012 Jun;139(6-7):459-67. doi: 10.1016/j.annder.2012.03.012. Epub 2012 Apr 17. Review. French.

PMID:
22721478
9.

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, Wallace CA, Onel KB, Foell D, Wu R, Biedermann S, Hamilton JD, Radin AR.

Arthritis Rheum. 2013 Sep;65(9):2486-96. doi: 10.1002/art.38042.

10.

[Schnitzler syndrome: case report, the experience with glucocorticoid and anakinra (Kineret) therapies and monitoring of systemic cytokine response].

Szturz P, Adam Z, Klabusay M, Fojtík Z, Kadanka Z, Stehlíková O, Chovancová J, Kalvodová L, Corbová D, Starý K, Neubauer J, Prásek J, Koukalová R, Rehák Z, Hájek R, Mayer J.

Vnitr Lek. 2011 Jan;57(1):97-112. Czech.

PMID:
21351669
11.

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.

de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW.

Ann Rheum Dis. 2006 Apr;65(4):542-4. Epub 2005 Aug 11.

12.

[Schnitzler syndrome: diagnostics and treatment].

Szturz P, Adam Z, Sedivá A, Fojtík Z, Corbová D, Neubauer J, Prásek J, Hájek R, Mayer J.

Klin Onkol. 2011;24(4):271-7. Review. Czech.

PMID:
21905617
13.

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A.

Ann Rheum Dis. 2009 Oct;68(10):1613-7. doi: 10.1136/ard.2009.108936. Epub 2009 Jul 26.

14.

Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature.

Tinazzi E, Puccetti A, Patuzzo G, Sorleto M, Barbieri A, Lunardi C.

Autoimmun Rev. 2011 May;10(7):404-9. doi: 10.1016/j.autrev.2011.01.003. Epub 2011 Jan 20. Review.

PMID:
21256251
15.

Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.

de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A.

Ann Rheum Dis. 2013 Oct;72(10):1634-8. doi: 10.1136/annrheumdis-2012-202192. Epub 2012 Oct 19.

PMID:
23087179
16.

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).

Gillespie J, Mathews R, McDermott MF.

J Inflamm Res. 2010;3:1-8. Epub 2010 Jan 19.

17.

Schnitzler syndrome: treatment failure to rituximab but response to anakinra.

Eiling E, Möller M, Kreiselmaier I, Brasch J, Schwarz T.

J Am Acad Dermatol. 2007 Aug;57(2):361-4. Epub 2007 Apr 30.

PMID:
17467852
18.

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

Radin A, Marbury T, Osgood G, Belomestnov P.

J Clin Pharmacol. 2010 Jul;50(7):835-41. doi: 10.1177/0091270009351882. Epub 2009 Dec 24.

PMID:
20035038
19.

[Schnitzlers SyndromeDifferential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra].

Adam Z, Šedivá A, Koukalová R, Řehák Z, Petrášová H, Szturz P, Adamová Z, Vetešníková E, Pour L, Krejčí M, Sandecká V, Pourová E, Čermáková Z, Ševčíková S, Král Z, Mayer J.

Vnitr Lek. Fall 2016;62(9):713-727. Review. Czech.

PMID:
27715073
20.

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

Sönnichsen A, Saulite I, Mangana J, Kerl K, Mehra T, Desislava I, Chang YT, Petrausch U, Schmid-Grendelmeier P, Hoetzenecker W, Cozzio A, Guenova E.

J Dermatolog Treat. 2016 Oct;27(5):436-8. doi: 10.3109/09546634.2015.1136048. Epub 2016 Feb 10.

PMID:
26864191

Supplemental Content

Support Center